|
2022 Journal Article Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trialMallory, Raburn M., Formica, Neil, Pfeiffer, Susan, Wilkinson, Bethanie, Marcheschi, Alex, Albert, Gary, McFall, Heather, Robinson, Michelle, Plested, Joyce S., Zhu, Mingzhu, Cloney-Clark, Shane, Zhou, Bin, Chau, Gordon, Robertson, Andreana, Maciejewski, Sonia, Hammond, Holly L., Baracco, Lauren, Logue, James, Frieman, Matthew B., Smith, Gale, Patel, Nita, Glenn, Gregory M., Adams, Mark, Arya, Mark, Athan, Eugene, Berger, Ira, Bradley, Paul, Briskin, Toby, Glover II, Richard ... Turner, Mark (2022). Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. The Lancet Infectious Diseases, 22 (11), 1565-1576. doi: 10.1016/S1473-3099(22)00420-0 |
|
2022 Book Frontiers of COVID-19: Scientific and clinical aspects of the novel coronavirus 2019Sasan Adibi, Paul Griffin, Melvin Sanicas, Maryam Rashidi and Francesco Lanfranchi eds. (2022). Frontiers of COVID-19: Scientific and clinical aspects of the novel coronavirus 2019. Cham, Switzerland: Springer. doi: 10.1007/978-3-031-08045-6 |
|
2022 Journal Article Japanese encephalitis - a recent rise in Australian casesArmstrong, Mark, Grey, Victoria and Griffin, Paul (2022). Japanese encephalitis - a recent rise in Australian cases. Medicine Today, 23 (8), 49-53. |
|
2022 Journal Article Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trialEvans, Thomas G, Bussey, Louise, Eagling-Vose, Elizabeth, Rutkowski, Kathryn, Ellis, Chris, Argent, Chris, Griffin, Paul, Kim, Joshua, Thackwray, Susan, Shakib, Sepehr, Doughty, Julia, Gillies, John, Wu, Jian, Druce, Julian, Pryor, Melinda and Gilbert, Sarah (2022). Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial. The Lancet Infectious Diseases, 22 (6), 857-866. doi: 10.1016/S1473-3099(21)00702-7 |
|
2022 Journal Article Ultrastructural insight into SARS-CoV-2 entry and budding in human airway epitheliumPinto, Andreia L., Rai, Ranjit K., Brown, Jonathan C., Griffin, Paul, Edgar, James R., Shah, Anand, Singanayagam, Aran, Hogg, Claire, Barclay, Wendy S., Futter, Clare E. and Burgoyne, Thomas (2022). Ultrastructural insight into SARS-CoV-2 entry and budding in human airway epithelium. Nature Communications, 13 (1) 1609, 1-14. doi: 10.1038/s41467-022-29255-y |
|
2022 Journal Article Safety, tolerability, pharmacokinetics, and pharmacodynamics of coadministered Ruxolitinib and Artemether-Lumefantrine in healthy adultsChughlay, M. Farouk, Barnes, Karen I., El Gaaloul, Myriam, Abla, Nada, Möhrle, Jörg J., Griffin, Paul, van Giersbergen, Paul, Reuter, Stephanie E., Schultz, Hayley B., Kress, Anita, Tapley, Peter, Webster, Rebecca A., Wells, Timothy, McCarthy, James S., Barber, Bridget E., Marquart, Louise, Boyle, Michelle J., Engwerda, Christian R. and Chalon, Stephan (2022). Safety, tolerability, pharmacokinetics, and pharmacodynamics of coadministered Ruxolitinib and Artemether-Lumefantrine in healthy adults. Antimicrobial Agents and Chemotherapy, 66 (1) e01584-21, e0158421. doi: 10.1128/AAC.01584-21 |
|
2022 Book Chapter The Road Ahead (Editors)Adibi, Sasan, Griffin, Paul, Sanicas, Melvin, Rashidi, Maryam and Lanfranchi, Francesco (2022). The Road Ahead (Editors). Frontiers of COVID-19: Scientific and Clinical Aspects of the Novel Coronavirus 2019. (pp. 639-650) edited by Sasan Adibi, Paul Griffin, Melvin Sanicas, Maryam Rashidi and Francesco Lanfranchi. Cham, Switzerland: Springer Nature Switzerland. doi: 10.1007/978-3-031-08045-6_31 |
|
2021 Journal Article Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccineWebster, Rebecca, Sekuloski, Silvana, Odedra, Anand, Woolley, Stephen, Jennings, Helen, Amante, Fiona, Trenholme, Katharine R., Healer, Julie, Cowman, Alan F., Eriksson, Emily M., Sathe, Priyanka, Penington, Jocelyn, Blanch, Adam J., Dixon, Matthew W. A., Tilley, Leann, Duffy, Michael F., Craig, Alister, Storm, Janet, Chan, Jo-Anne, Evans, Krystal, Papenfuss, Anthony T., Schofield, Louis, Griffin, Paul, Barber, Bridget E., Andrew, Dean, Boyle, Michelle J., de Labastida Rivera, Fabian, Engwerda, Christian and McCarthy, James S. (2021). Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine. BMC Medicine, 19 (1) 293, 293. doi: 10.1186/s12916-021-02150-x |
|
2021 Journal Article Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trialChappell, Keith J., Mordant, Francesca L., Li, Zheyi, Wijesundara, Danushka K., Ellenberg, Paula, Lackenby, Julia A., Cheung, Stacey T. M., Modhiran, Naphak, Avumegah, Michael S., Henderson, Christina L., Hoger, Kym, Griffin, Paul, Bennet, Jillian, Hensen, Luca, Zhang, Wuji, Nguyen, Thi H. O., Marrero-Hernandez, Sara, Selva, Kevin J., Chung, Amy W., Tran, Mai H., Tapley, Peter, Barnes, James, Reading, Patrick C., Nicholson, Suellen, Corby, Stavroula, Holgate, Thomas, Wines, Bruce D., Hogarth, P Mark, Kedzierska, Katherine ... Munro, Trent P. (2021). Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet Infectious Diseases, 21 (10), 1383-1394. doi: 10.1016/S1473-3099(21)00200-0 |
|
2021 Journal Article A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patientsYamada, Miko, Miller, Dennis M., Lowe, Melinda, Rowe, Casey, Wood, Dominic, Soyer, H. Peter, Byrnes-Blake, Kelly, Parrish-Novak, Julia, Ishak, Laura, Olson, James M., Brandt, Gordon, Griffin, Paul, Spelman, Lynda and Prow, Tarl W. (2021). A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients. Contemporary Clinical Trials Communications, 23 100830, 1-6. doi: 10.1016/j.conctc.2021.100830 |
|
2021 Journal Article Addressing the crisis of congenital syphilis: Key findings from an evaluation of the management of syphilis in pregnancy and the newborn in South‐East QueenslandWu, Mandy, Seel, Mandy, Britton, Sumudu, Dean, Judith A., Lazarou, Mattea, Safa, Huda, Griffin, Paul and Nourse, Clare (2021). Addressing the crisis of congenital syphilis: Key findings from an evaluation of the management of syphilis in pregnancy and the newborn in South‐East Queensland. Australian and New Zealand Journal of Obstetrics and Gynaecology, 62 (1) ajo.13424, 91-97. doi: 10.1111/ajo.13424 |
|
2021 Journal Article Pentosan polysulfate sodium for Ross River virus-induced arthralgia: a phase 2a, randomized, double-blind, placebo-controlled studyKrishnan, Ravi, Duiker, Melanie, Rudd, Penny A., Skerrett, Donna, Pollard, James G. D., Siddel, Carolyn, Rifat, Rifat, Ng, Jennifer H. K., Georgius, Peter, Hererro, Lara J. and Griffin, Paul (2021). Pentosan polysulfate sodium for Ross River virus-induced arthralgia: a phase 2a, randomized, double-blind, placebo-controlled study. BMC Musculoskeletal Disorders, 22 (1) 271. doi: 10.1186/s12891-021-04123-w |
|
2021 Journal Article Defining the antimalarial activity of cipargamin in healthy volunteers experimentally infected with blood-stage Plasmodium falciparumMcCarthy, James S., Abd-Rahman, Azrin N., Collins, Katharine A., Marquart, Louise, Griffin, Paul, Kummel, Anne, Fuchs, Aline, Winnips, Cornelis, Mishra, Vishal, Csermak-Renner, Katalin, Jain, J. Prakash and Gandhi, Preetam (2021). Defining the antimalarial activity of cipargamin in healthy volunteers experimentally infected with blood-stage Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 65 (2) e01423-20. doi: 10.1128/aac.01423-20 |
|
2020 Journal Article Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccineKeech, Cheryl, Albert, Gary, Cho, Iksung, Robertson, Andreana, Reed, Patricia, Neal, Susan, Plested, Joyce S., Zhu, Mingzhu, Cloney-Clark, Shane, Zhou, Haixia, Smith, Gale, Patel, Nita, Frieman, Matthew B., Haupt, Robert E., Logue, James, McGrath, Marisa, Weston, Stuart, Piedra, Pedro A., Desai, Chinar, Callahan, Kathleen, Lewis, Maggie, Price-Abbott, Patricia, Formica, Neil, Shinde, Vivek, Fries, Louis, Lickliter, Jason D., Griffin, Paul, Wilkinson, Bethanie and Glenn, Gregory M. (2020). Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. The New England Journal of Medicine, 383 (24), 2320-2332. doi: 10.1056/NEJMoa2026920 |
|
2020 Journal Article A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adultsAliprantis, Antonios O., Shaw, Christine A., Griffin, Paul, Farinola, Nicholas, Railkar, Radha A., Cao, Xin, Liu, Wen, Sachs, Jeffrey R., Swenson, Christine J., Lee, Heather, Cox, Kara S., Spellman, Daniel S., Winstead, Colleen J., Smolenov, Igor, Lai, Eseng, Zaks, Tal, Espeseth, Amy S. and Panther, Lori (2020). A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Human Vaccines and Immunotherapeutics, 17 (5), 1-14. doi: 10.1080/21645515.2020.1829899 |
|
2020 Journal Article Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO studyHenderson, A., Paterson, D. L., Chatfield, M. D., Tambyah, P. A., Lye, D. C., De, P. P., Lin, R. T. P., Chew, K. L., Yin, M., Lee, T. H., Yilmaz, M., Cakmak, R., Alenazi, T. H., Arabi, Y. M., Falcone, M., Bassetti, M., Righi, E., Rogers, B.A., Kanj, S. S., Bhally, H., Iredell, J., Mendelson, M., Boyles, T. H., Looke, D. F. M., Runnegar, N. J., Miyakis, S., Walls, G., AI Khamis, M., Zikri, A. ... For the MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN) (2020). Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study. Clinical Infectious Diseases, 73 (11), e3842-e3850. doi: 10.1093/cid/ciaa1479 |
|
2020 Journal Article Pharmacokinetics and pharmacodynamics of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: a randomized, double-blind trialLickliter, Jason, Kanceva, Radmila, Vincent, Emmanuelle, Schueler, Armin, Harrison-Moench, Eleanor, Yue, Corinne Seng, Stahl, Michael, Ullmann, Martin, Ghori, Vishal and Griffin, Paul (2020). Pharmacokinetics and pharmacodynamics of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: a randomized, double-blind trial. Clinical Therapeutics, 42 (8), 1508-1518.e1. doi: 10.1016/j.clinthera.2020.05.020 |
|
2020 Journal Article Antimalarial activity of artefenomel against asexual parasites and transmissible gametocytes during experimental blood-stage Plasmodium vivax infectionCollins, Katharine A., Abd-Rahman, Azrin N., Marquart, Louise, Ballard, Emma, Gobeau, Nathalie, Griffin, Paul, Chalon, Stephan, Möhrle, Jörg J. and McCarthy, James S. (2020). Antimalarial activity of artefenomel against asexual parasites and transmissible gametocytes during experimental blood-stage Plasmodium vivax infection. The Journal of Infectious Diseases, 225 (6), 1062-1069. doi: 10.1093/infdis/jiaa287 |
|
2020 Journal Article Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 studyPlayford, Elliott Geoffrey, Munro, Trent, Mahler, Stephen M., Elliott, Suzanne, Gerometta, Michael, Hoger, Kym L., Jones, Martina L., Griffin, Paul, Lynch, Kathleen D., Carroll, Heidi, El Saadi, Debra, Gilmour, Margaret E., Hughes, Benjamin, Hughes, Karen, Huang, Edwin, de Bakker, Christopher, Klein, Reuben, Scher, Mark G., Smith, Ina L., Wang, Lin-Fa, Lambert, Stephen B., Dimitrov, Dimiter S., Gray, Peter P. and Broder, Christopher C. (2020). Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study. The Lancet Infectious Diseases, 20 (4), 445-454. doi: 10.1016/S1473-3099(19)30634-6 |
|
2020 Journal Article A single-dose combination study with the experimental antimalarials artefenomel and DSM265 to determine safety and antimalarial activity against blood-stage Plasmodium falciparum in healthy volunteersMcCarthy, James S., Rückle, Thomas, Elliott, Suzanne L., Ballard, Emma, Collins, Katharine A., Marquart, Louise, Griffin, Paul, Chalon, Stephan and Möhrle, Jörg J. (2020). A single-dose combination study with the experimental antimalarials artefenomel and DSM265 to determine safety and antimalarial activity against blood-stage Plasmodium falciparum in healthy volunteers. Antimicrobial Agents and Chemotherapy, 64 (1) e01371-19, e01371-19. doi: 10.1128/AAC.01371-19 |
